摘要
背景:吉氏甲醚(Gm)是钩藤中吲哚生物碱之一,是尤库坎的有效成分,能改善精神错乱的行为和心理症状。a(Bpsd)在几种类型的痴呆症患者。GM的药理作用与5-羟色胺(5-HT)受体亚型有关. 目的:利用我们自己的数据和前人的研究成果,对GM与脑内5-HT受体亚型的结合特性进行综述。 方法:对几种5-羟色胺受体亚型进行竞争性受体结合和激动剂/拮抗剂活性测定。此外,本文还描述了药物动力学和脑分布。在PubMed上搜索了GM的基因。 结果:GM与5-HT1A、5-HT1B、5-HT2A、5-HT2B、5-HT2C、5-HT4、5-HT5A、5-HT6、5-HT7等5-HT受体亚型结合.。在这些受体中,gm对5-hT1A Re具有部分激动剂活性。5-HT2A、5-HT2B、5-HT2C和5-HT7受体的受体及其拮抗活性。此外,GM还被各种CYP亚型代谢,主要是CYP3A4。在血液中检测到亲本/未改变的gm基因。大鼠口服YKS后的ND脑。在大脑中,gm主要与神经元样大细胞上的5-HT1A、5-HT2A、5-HT2B、5-HT2C和5-HT7受体结合,主要在额叶皮质。[医] 十分之一效度(顺势疗法),金伯克氏X线剂量单位 结论:GM是一种具有重要药理作用的生物碱,通过与多种5-HT受体亚型结合,调节多种5-羟色胺的活性或功能。因此,回顾了最近的5-HT受体相关的证据表明转基因对YKS药理作用的部分原因。
关键词: 葛根素甲醚,5-羟色胺受体,药动学,药理学方面,尤库桑,BPSD,痴呆。
Current Medicinal Chemistry
Title:Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook
Volume: 25 Issue: 9
关键词: 葛根素甲醚,5-羟色胺受体,药动学,药理学方面,尤库桑,BPSD,痴呆。
摘要: Background: Geissoschizine methyl ether (GM) is one of the indole alkaloids in Uncaria hook, and an active ingredient of yokukansan (YKS) that improves behavioral and psychological symptoms of dementia (BPSD) in patients with several types of dementia. The pharmacological action of GM has been related to various serotonin (5-HT) receptor subtypes.
Objective: The aim of this article is to review the binding characteristics of GM to the 5-HT receptor subtypes in the brains using our own data and previous findings.
Method: Competitive receptor-binding and agonist/antagonist activity assays for several 5-HT receptor subtypes were performed. Moreover, the articles describing pharmacokinetics and brain distribution of GM were searched in PubMed.
Results: GM bound the following 5-HT receptor subtypes: 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5- HT4, 5-HT5A, 5-HT6, and 5-HT7. Among these receptors, GM had partial agonistic activity for 5-HT1A receptors and antagonistic activity for 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors. Also, GM was metabolized by various CYP isoforms, mainly CYP3A4. Parent/unchanged GM was detected in both the blood and brain of rats after oral administration of YKS. In the brains, GM was presumed to bind to 5- HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors on neuron-like large cells mainly in the frontal cortex.
Conclusion: These results suggest that GM is a pharmacologically important alkaloid that regulates various serotonergic activities or functions by binding to multiple 5-HT receptor subtypes. Thus, this review provides recent 5-HT receptor-related evidence that GM is partly responsible for pharmacological effects of YKS.
Export Options
About this article
Cite this article as:
Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook, Current Medicinal Chemistry 2018; 25 (9) . https://dx.doi.org/10.2174/0929867324666170320114713
DOI https://dx.doi.org/10.2174/0929867324666170320114713 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exercise Prescription for Post-Menopausal Women with Obesity
Current Women`s Health Reviews Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Olfactory Dysfunction and Cognitive Impairment in Age-Related Neurodegeneration: Prevalence Related to Patient Selection, Diagnostic Criteria and Therapeutic Treatment of Aged Clients Receiving Clinical Neurology and Community-Based Care
Current Clinical Pharmacology Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Current Pharmaceutical Design Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Commentary on Neuronal Degeneration and Cell Death in Guam ALS and PD: An Evolutionary Process of Understanding
Current Alzheimer Research Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry Niacin: From Mechanisms of Action to Therapeutic Uses
Mini-Reviews in Medicinal Chemistry Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets The Role of Atropine Eye Drops in Myopia Control
Current Pharmaceutical Design Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Current Alzheimer Research Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Does Non-Invasive Brain Stimulation Improve Cognition in Major Depressive Disorder? A Systematic Review
CNS & Neurological Disorders - Drug Targets Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research